COCHLEAR ™ NUCLEUS ®
RELIABILITY REPORT
Volume 14 | February 2016
OUR MISSION
We help people hear and be heard.
We empower people to connect with others and live a full life.
We transform the way people understand and treat hearing loss.
We innovate and bring to market a range of implantable hearing solutions that deliver a
lifetime of hearing outcomes.
Cochlear’s implants are the most reliable in the industry. That’s one reason why more people
choose Cochlear than any other implant brand.
COCHLEAR'S IMPLANTS
ARE THE MOST RELIABLE
IN THE INDUSTRY
4,5
Cochlear Nucleus Reliability Report | February 2016
3
WHY RELIABILITY MATTERS
High implant reliability means greater patient satisfaction and less risk of additional surgery.
When considering which implant is right for your patient, it's important that you have access
to the latest data on short- and long-term reliability, success and failure rates and key implant
features. These are outlined in this Reliability Report.
ABOUT RELIABILITY REPORTING
The global standards for cochlear implant reliability reporting are the International Standard
ISO 5841-2:20141, the reporting principles outlined in the European consensus statement
on cochlear implant failures and explantations 2, and expert recommendations from
the International classification of reliability for implanted cochlear implant receiver
stimulators.3
Cochlear complies with these standards.
HOW TO READ THIS REPORT
What is Cumulative Survival Percentage (CSP)?
What data is in
this report?
The cumulative percentage of functioning implants over time, which can be used to
predict the reliability of the device within a given time period.
The data in this report
cover the entire life of
implant models and
registered implants*
worldwide.
The reliability calculations used in this report are in accordance with the ISO 58412:2014 Standard.1 They are probability calculations, which use a modified Kaplan-Meier
estimator. These data estimate the probability of survival within a period of time and
are represented as Cumulative Survival Percentage (CSP).
MORE PEOPLE CHOOSE COCHLEAR
THAN ANY OTHER IMPLANT BRAND
OVER 280,000
REGISTERED COCHLEAR
NUCLEUS® IMPLANTS
WORLDWIDE
Nucleus Implant Reliability
Number of registered implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
6,935
5,290
12,225
153,600
Profile
CI24RE
69,160
84,440
CI500
15,381
14,388
29,769
CI24R
18,807
34,521
53,328
CI24M (All)
7,886
11,824
19,710
CI22M
9,959
8,224
18,183
Cumulative Survival Percentage (CSP) data for combined adults and children
YEARS
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
CI22M
99.3 98.7 98.2 97.8 97.5 97.2 97.0 96.7 96.5 96.2 96.0 95.7 95.5 95.3 95.0 94.9 94.7 94.5 94.1 93.9 93.7 93.4 93.2 92.9 92.4 92.2 92.1 92.1 92.1
CI24M (All)
99.5 98.9 98.5 98.2 98.0 97.9 97.7 97.6 97.5 97.3 97.2 97.1 97.1 97.0 97.0 96.9 96.9 96.8 96.8
CI24R
99.7 99.5 99.3 99.1 99.0 98.8 98.6 98.5 98.3 98.2 98.1 98.1 97.9 97.8 97.7 97.4
CI24RE
99.8 99.7 99.6 99.5 99.4 99.3 99.3 99.2 99.2 99.1 99.0
CI500
96.3 93.9 92.8 92.0 91.5 91.3 91.3
Profile
99.97 99.97
Previous generation implant
Current generation implant
PROFILE 99.97%
100
CI24RE 99.00%
CI24R 97.40%
98
CI24M (ALL) 96.80%
Cumulative Survival Percentage of Implants
DEVICE
96
94
92
CI500* 91.30%
CI22M 92.10%
90
PROFILE 99.97%
CSP WITHIN TWO YEARS
CI24RE 99% CSP
WITHIN 11 YEARS
88
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Time in Years
REGISTERED IMPLANT DATA COMBINED FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
* Voluntarily recalled in September 2011.
8
Cochlear Nucleus Reliability Report | February 2016
Cochlear Nucleus Reliability Report | February 2016
9
What is combined data?
How are results shown?
The cumulative survival
percentage of both adults and
children populations combined.
Results for adults and children
are shown separately with
95% confidence intervals ( )
as required by the consensus
statement.
* An implant is registered with Cochlear when clinic/hospital submits the registration
of the implanted device. Implant registrations often lag behind surgery dates.
Cochlear Nucleus Reliability Report | February 2016
5
COMPLIANCE WITH INTERNATIONAL
REPORTING STANDARDS
In 2005, the major European cochlear implant centres, global
regulatory authorities and device manufacturers developed
the European consensus statement on cochlear implant failures
and explantations.2 The consensus statement outlines how
device failures and reliability should be reported, and the seven
principles of best practice reporting.
CONSENSUS STATEMENT PRINCIPLES
All device failures must be reported to the
competent authority and must be included
in the calculation of the Cumulative Survival
Rate (CSR*). Reporting of the CSR should be in
accordance with ISO Standard 5841-2:2000.1
Manufacturer's reports of device failure should
indicate the sources of data and the sample size.
There must be no exclusions. The time period over
which the data was collected should be specified.
Reports of CSR should give complete historical
data of a given device, describing any technical
modifications (which can be integrated into
historical data by starting at time 0).
The complete data set of the ‘mother’ product
should always be supplied when presenting data
on subsequent device modifications.
A new device can be attributed when there has
been a change in either the case and/or the
electrodes and/or the electronics and has been
labelled by its own CE mark.
Cumulative Survival Rate should be split into data
for adults and for children and 95% confidence
intervals (80% or 90% if the population is below
1,000 units) should be provided.
Device survival time starts to count with closure of
the wound intraoperatively.
* CSR is identical to to Cumulative Survival Percentage (CSP).
6
Cochlear Nucleus Reliability Report | February 2016
COCHLEAR REPORTING PRACTICE
COCHLEAR
COMPLIANCE
MED-EL
COMPLIANCE4
ADVANCED BIONICS
COMPLIANCE5
All device failures are reported to the competent
authority.
Cochlear uses the applicable definitions,
categorisation scheme and calculation
procedures of ISO 5841-2:20001 and the updated
version published in 2014.
All device failure modes are included, including
failures due to external impact.
The source of data is Cochlear’s global
complaints handling database.
Sample size and time period are specified with
each report.
Sample size not included.
All models and all versions of each model are
included in reports.
Descriptions of any significant technical
modfications are given.
Reports aggregate the reliability of all devices
(pre- and post- modification). If the postmodification is significantly different, postmodification is reported separately from the
aggregate of all devices.
A new device is attributed when there has been
a change in either the case and/or the electrodes
and/or the electronics and has been labelled
by its own CE mark. Market practice is that all
cochlear implants are labeled by one CE mark per
authority.
COMBI 40+ no
longer reported.
PULSAR no longer reported.
COMBI 40+ no
longer reported.
PULSAR no longer reported.
Clarion C1.0 no
longer reported.
Not explicitly stated.
Not explicitly stated.
Reports show separate data for adults and
children.
This Nucleus® Reliability Report contains
reliability data with 95% confidence intervals, in
compliance with the consensus statement.2,3
No split data on
adults and children.
Confidence intervals
not included.
All failures are counted that occur any time after
wound closure.
Not explicitly stated.
Cochlear Nucleus Reliability Report | February 2016
7
MORE PEOPLE CHOOSE COCHLEAR
THAN ANY OTHER IMPLANT BRAND
OVER 280,000
REGISTERED COCHLEAR
NUCLEUS® IMPLANTS
WORLDWIDE
Number of registered implants - 1 February 2016
DEVICE
ADULTS
CHILDREN
COMBINED
Profile
6,935
5,290
12,225
CI24RE
69,160
84,440
153,600
CI500
15,381
14,388
29,769
CI24R
18,807
34,521
53,328
CI24M (All)
7,886
11,824
19,710
CI22M
9,959
8,224
18,183
Cumulative Survival Percentage (CSP) data for combined adults and children
YEARS
8
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
CI22M
99.3 98.7 98.2 97.8 97.5 97.2 97.0 96.7 96.5 96.2 96.0 95.7 95.5 95.3 95.0 94.9 94.7 94.5 94.1 93.9 93.7 93.4 93.2 92.9 92.4 92.2 92.1 92.1 92.1
CI24M (All)
99.5 98.9 98.5 98.2 98.0 97.9 97.7 97.6 97.5 97.3 97.2 97.1 97.1 97.0 97.0 96.9 96.9 96.8 96.8
CI24R
99.7 99.5 99.3 99.1 99.0 98.8 98.6 98.5 98.3 98.2 98.1 98.1 97.9 97.8 97.7 97.4
CI24RE
99.8 99.7 99.6 99.5 99.4 99.3 99.3 99.2 99.2 99.1 99.0
CI500
96.3 93.9 92.8 92.0 91.5 91.3 91.3
Profile
99.97 99.97
Cochlear Nucleus Reliability Report | February 2016
Nucleus Implant Reliability
Previously available implant
Currently available implant
PROFILE 99.97%
100
CI24RE 99.00%
CI24R 97.40%
98
Cumulative Survival Percentage of Implants
CI24M (ALL) 96.80%
96
94
92
CI500* 91.30%
CI22M 92.10%
90
PROFILE 99.97%
CSP WITHIN TWO YEARS
CI24RE 99% CSP
WITHIN 11 YEARS
88
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Time in Years
REGISTERED IMPLANT DATA COMBINED FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
* Voluntarily recalled in September 2011.
Cochlear Nucleus Reliability Report | February 2016
9
Natalie S.
Cochlear recipient since 2015
CURRENTLY AVAILABLE IMPLANTS
Cochlear Nucleus Reliability Report | February 2016
11
NUCLEUS PROFILE SERIES IMPLANT
Number of registered Profile Series implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
6,935
5,290
12,225
At only 3.9 mm, the thin implant body of the Profile Series is the most discreet choice for all patients.
The implant also offers ease of use and faster surgery due to minimal drilling.
Commercially released in 2014, the Profile Series sets a new standard in implant reliability with a 99.97%
combined Cumulative Survival Percentage within two years.
Profile Series Cumulative Survival Percentage
YEAR
1
2
Adults
99.95
99.95
Children
100.00
100.00
Combined
99.97
99.97
3.9 mm
12
Cochlear Nucleus Reliability Report | February 2016
Profile Series Reliability
Adults
Cumulative Survival Percentage of Implants
100
Children
CHILDREN 100.00%
ADULTS 99.95%
99
PROFILE:
OVER 12,000 DEVICES
IMPLANTED
98
99.97% CSP WITHIN
TWO YEARS
97
96
95
0
1
2
Time in Years
REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
Cochlear Nucleus Reliability Report | February 2016
13
NUCLEUS CI24RE SERIES IMPLANT
Number of registered CI24RE Series implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
69,160
84,440
153,600
The CI24RE Series is the world’s most widely used cochlear implant.
Released in 2005, it has a record of 99% combined Cumulative Survival Percentage within 11 years.
CI24RE Series Cumulative Survival Percentage
YEARS
14
1
2
3
4
5
6
7
8
9
10
11
Adults
99.9
99.8
99.7
99.7
99.6
99.5
99.5
99.5
99.4
99.4
99.4
Children
99.8
99.7
99.5
99.4
99.3
99.2
99.1
99.1
99.0
98.8
98.6
Combined
99.8
99.7
99.6
99.5
99.4
99.3
99.3
99.2
99.2
99.1
99.0
Cochlear Nucleus Reliability Report | February 2016
CI24RE Series Reliability
ADULTS 99.4%
CHILDREN 98.6%
98
Cumulative Survival Percentage of Implants
Children
Adults
100
96
94
CI24RE:
OVER 150,000 DEVICES
IMPLANTED
92
90
99% CSP WITHIN
11 YEARS
88
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
11
12
13
Time in Years
REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
Cochlear Nucleus Reliability Report | February 2016
15
Rod Saunders
First research multi-channel
cochlear implant recipient, 1978
PREVIOUSLY AVAILABLE IMPLANTS 17
Cochlear Nucleus Reliability Report | February 2016
17
NUCLEUS CI500 SERIES IMPLANT
Number of registered CI500 Series implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
15,381
14,388
29,769
Released in 2009, the CI500 Series has a combined Cumulative Survival Percentage of 91.3%
within seven years.
The CI500 Series was voluntarily recalled in September 2011.
CI500 Series Cumulative Survival Percentage
YEARS
18
1
2
3
4
5
6
7
Adults
95.9
93.9
92.8
92.3
91.9
91.7
91.7
Children
96.6
94.0
92.7
91.7
91.1
90.9
90.8
Combined
96.3
93.9
92.8
92.0
91.5
91.3
91.3
Cochlear Nucleus Reliability Report | February 2016
CI500 Series Reliability
Adults
100
Children
Cumulative Survival Percentage of Implants
98
96
94
92
ADULTS 91.7%
CHILDREN 90.8%
90
88
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
Time in Years
REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
Cochlear Nucleus Reliability Report | February 2016
19
NUCLEUS CI24R IMPLANT
Number of registered CI24R implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
18,807
34,521
53,328
The CI24R was released in 2000 with perimodiolar (Contour Advance®) and straight electrodes.
Within 16 years, the CI24R implant has a combined Cumulative Survival Percentage of 97.4%.
CI24R Cumulative Survival Percentage
YEARS
20
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Adults
99.8
99.7
99.5
99.4
99.3
99.1
99.0
98.9
98.9
98.7
98.7
98.6
98.6
98.5
98.5
98.3
Children
99.7
99.4
99.1
99.0
98.8
98.6
98.3
98.2
98.0
97.9
97.8
97.7
97.5
97.3
97.2
96.8
Combined
99.7
99.5
99.3
99.1
99.0
98.8
98.6
98.5
98.3
98.2
98.1
98.1
97.9
97.8
97.7
97.4
Cochlear Nucleus Reliability Report | February 2016
CI24R Reliability
Children
Adults
100
ADULTS 98.3%
98
Cumulative Survival Percentage of Implants
CHILDREN 96.8%
96
94
92
90
88
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Time in Years
REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
Cochlear Nucleus Reliability Report | February 2016
21
NUCLEUS CI24M IMPLANT
Number of registered CI24M implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
ALL
7,886
11,824
19,710
POST**
6,169
9,313
15,482
Released in 1997, the CI24M implant was the world’s first cochlear implant with a removable magnet
for MRI safety.
Within 19 years, the CI24M implant has a combined Cumulative Survival Percentage of 96.8%.
CI24M Cumulative Survival Percentage
YEARS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Adults
(All)
99.8
99.7
99.7
99.6
99.5
99.5
99.4
99.4
99.3
99.2
99.1
99.0
99.0
98.9
98.9
98.8 98.8 98.6
98.6
Children
(All)
99.2
98.3
97.7
97.3
97.0
96.8
96.6
96.4
96.3
96.1
96.0
95.9
95.8
95.8
95.7
95.7
95.6
Adults
(Post)
99.9
99.8
99.7
99.6
99.5
99.5
99.4
99.3
99.3
99.2
99.1
99.0
99.0
98.9
98.9
98.8 98.8 98.8
#
Children
(Post)
99.4
98.6
98.1
97.8
97.5
97.3
97.2
97.0
96.8
96.7
96.5
96.5
96.4
96.3
96.3
96.2
96.2
96.2
#
Combined
(All)
99.5
98.9
98.5
98.2
98.0
97.9
97.7
97.6
97.5
97.3
97.2
97.1
97.1
97.0
97.0
96.9
96.9
96.8
96.8
** ‘Post’ refers to the addition of a structural support component to improve impact strength.
# Individual populations are less than the minimum required for a valid calculation.1
22
Cochlear Nucleus Reliability Report | February 2016
16
17
95.6
18
95.6
19
CI24M Reliability
Adults (Post)
100
Adults (All)
ADULTS (POST) 98.8%
98
Cumulative Survival Percentage of Implants
Children (All)
Children (Post)
ADULTS (ALL) 98.6%
96
CHILDREN (POST) 96.2%
CHILDREN (ALL) 95.6%
94
92
90
88
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Time in Years
REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
Cochlear Nucleus Reliability Report | February 2016
23
NUCLEUS CI22M IMPLANT
Number of registered CI22M implants - 1 February 2016
ADULTS
CHILDREN
COMBINED
9,959
8,224
18,183
Released in 1985, the CI22M implant was the first commercially available multi-channel cochlear implant
in the world.
Within 29 years, the CI22M implant has a combined Cumulative Survival Percentage of 92.1%.
CI22M Cumulative Survival Percentage
YEARS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Adults
99.3
99.0
98.7
98.5
98.4
98.3
98.2
98.0
97.9
97.6
97.5
97.4
97.2
96.9
Children
99.2
98.3
97.6
96.9
96.5
96.0
95.5
95.2
94.8
94.5
94.2
93.8
93.6
93.3
Combined
99.3
98.7
98.2
97.8
97.5
97.2
97.0
96.7
96.5
96.2
96.0
95.7
95.5
95.3
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
96.7
96.6
96.4
96.2
95.9
95.7
95.5
95.2
95.0
94.6
94.1
94.0
93.9
93.9
93.9
93.0
92.8
92.7
92.4
92.1
91.8
91.5
91.3
91.1
90.8
90.5
90.1
90.1
#
#
95.0
94.9
94.7
94.5
94.1
93.9
93.7
93.4
93.2
92.9
92.4
92.2
92.1
92.1
92.1
# Individual populations are less than the minimum required for a valid calculation.1
24
Cochlear Nucleus Reliability Report | February 2016
CI22M Reliability
Children
Adults
100
Cumulative Survival Percentage of Implants
98
ADULTS 93.9%
96
94
92
90
88
CHILDREN 90.1%
86
84
82
80
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Time in Years
REGISTERED IMPLANT DATA FOR ADULTS AND CHILDREN AS OF 1 FEBRUARY 2016
Cochlear Nucleus Reliability Report | February 2016
25
APPENDIX
GRAPHICAL REPRESENTATION
Each graph represents a type of device based on the receiver/stimulator portion.
RECEIVER/
STIMULATOR
IMPLANTS*
Profile Series
Cochlear Nucleus Profile with Contour Advance Electrode (CI512)
Cochlear Nucleus Profile with Slim Straight Electrode (CI522)
CI24RE Series
Nucleus Freedom® with Contour Advance Electrode
Nucleus Freedom with Straight Electrode
Cochlear Nucleus CI422 Cochlear Implant
Cochlear Hybrid™ L24 Cochlear Implant
CI500 Series
Cochlear Nucleus CI512 Cochlear Implant
Cochlear Nucleus CI513 Cochlear Implant
Cochlear Nucleus CI551 Double Array Cochlear Implant
Cochlear Nucleus ABI541 Auditory Brainstem Implant
CI24R
Nucleus 24 with Contour Advance Electrode
Nucleus 24 with Contour® Electrode
Nucleus 24k with Straight Electrode
CI24M
Nucleus 24 with Straight Electrode
Nucleus 24 with Double Array
Nucleus 24 Auditory Brainstem Implant [ABI]
CI22M
Nucleus 22
* Implant availability varies by market.
REFERENCES
1. International standard ISO 5841-2. Implants for surgery — Cardiac Pacemakers — part 2: Reporting of clinical performance of populations of pulse
generators or leads. Geneva (Switzerland): International Organization for Standardization - initially published in 2000 and updated in 2014.
2. European consensus statement on cochlear implant failures and explantations. Otol Neurotol. 2005 Nov;26(6):1097-9.
3. Battmer RD, Backous DD, Balkany TJ, Briggs RJ, Gantz BJ, van Hasselt A, et al. International classification of reliability
for implanted cochlear implant receiver stimulators. Otol Neurotol. 2010 Oct;31(8):1190-3.
4. Reliability You Can Count On [Internet]. MED-EL. January 2016 [cited 17 March 2016].
Available from: http://www.medel.com/reliability-reporting/
5. 2015 Cochlear Implant Reliability Report [Internet]. Stäfa (Switzerland): Advanced Bionics AG; 2015 [cited 17 March 2016]; Available from: http://www.
advancedbionics.com/content/dam/ab/Global/en_ce/documents/candidate/028-M719-02_Global_2015_Implant_Reliability_Report_reference.pdf
26
Cochlear Nucleus Reliability Report | February 2016
As the global leader in implantable hearing solutions, Cochlear is dedicated to bringing
the gift of sound to people with moderate to profound hearing loss. We have helped
over 400,000 people of all ages live full and active lives by reconnecting them with
family, friends and community.
We aim to give our recipients the best lifelong hearing experience and access to
innovative future technologies. For our professional partners, we offer the industry's
Cochlear
Ltd (ABNresearch
96 002 618 073)
1 University
Avenue,networks.
Macquarie University, NSW 2109, Australia Tel: +61 2 9428 6555 Fax: +61 2 9428 6352
largest
clinical,
and
support
Cochlear Ltd (ABN 96 002 618 073) 14 Mars Road, Lane Cove, NSW 2066, Australia Tel: +61 2 9428 6555 Fax: +61 2 9428 6352
Cochlear Americas 13059 E Peakview Avenue, Centennial, CO 80111, USA Tel: +1 303 790 9010 Fax: +1 303 792 9025
Cochlear Canada Inc 2500-120 Adelaide Street West, Toronto, ON M5H 1T1, Canada Tel: +1 416 972 5082 Fax: +1 416 972 5083
Cochlear AG EMEA Headquarters, Peter Merian-Weg 4, 4052 Basel, Switzerland Tel: +41 61 205 0404 Fax: +41 61 205 0405
Cochlear Deutschland GmbH & Co. KG Karl-Wiechert-Allee 76A, 30625 Hannover, Germany Tel: +49 511 542 770 Fax: +49 511 542 7770
Cochlear Europe Ltd 6 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey KT15 2HJ, United Kingdom Tel: +44 1932 26 3400 Fax: +44 1932 26 3426
Cochlear Benelux NV Schaliënhoevedreef 20 i, B-2800 Mechelen, Belgium Tel: +32 15 79 55 11 Fax: +32 15 79 55 70
Cochlear France S.A.S. 135 Route de Saint-Simon, 31100 Toulouse, France Tel: +33 5 34 63 85 85 (International) or 0805 200 016 (National) Fax: +33 5 34 63 85 80
Cochlear Italia S.r.l. Via Larga 33, 40138 Bologna, Italy Tel: +39 051 601 53 11 Fax: +39 051 39 20 62
Cochlear Nordic AB Konstruktionsvägen 14, 435 33 Mölnlycke, Sweden Tel +46 31 335 14 61 Fax +46 31 335 14 60
Cochlear Tıbbi Cihazlar ve Sağlık Hizmetleri Ltd. Şti. Çubuklu Mah. Boğaziçi Cad., Boğaziçi Plaza No: 6/1, Kavacık, TR-34805 Beykoz-Istanbul, Turkey Tel: +90 216 538 5900 Fax: +90 216 538 5919
Cochlear (HK) Limited Room 1204, 12/F, CRE Building, No 303 Hennessy Road, Wanchai, Hong Kong SAR Tel: +852 2530 5773 Fax: +852 2530 5183
Cochlear Korea Ltd 1st floor, Cheongwon building, 828-5, Yuksam dong, Kangnam gu, Seoul, Korea Tel: +82 2 533 4663 Fax: +82 2 533 8408
Cochlear Limited (Singapore Branch) 6 Sin Ming Road, #01-16 Sin Ming Plaza Tower 2, Singapore 575585 Tel: +65 6553 3814 Fax: +65 6451 4105
Cochlear Medical Device (Beijing) Co., Ltd Unit 2208 Gemdale Tower B, 91 Jianguo Road, Chaoyang District, Beijing 100022, P.R. China Tel: +86 10 5909 7800 Fax: +86 10 5909 7900
Cochlear Medical Device Company India Pvt. Ltd. Ground Floor, Platina Building, Plot No C-59, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India Tel: +91 22 6112 1111 Fax: +91 22 6112 1100
株式会社日本コクレア
（Nihon Cochlear Co Ltd）
〒113-0033 東京都文京区本郷2-3-7 お茶の水元町ビル Tel: +81 3 3817 0241 Fax: +81 3 3817 0245
Cochlear Middle East FZ-LLC Dubai Healthcare City, Al Razi Building 64, Block A, Ground Floor, Offices IR1 and IR2, Dubai, United Arab Emirates Tel: +971 4 818 4400 Fax: +971 4 361 8925
Cochlear Latinoamérica S.A. International Business Park, Building 3835, Office 103, Panama Pacifico, Panama Tel: +507 830 6220 Fax: +507 830 6218
Cochlear Ltd (ABN 96 002 618 073) 1 University Avenue, Macquarie University, NSW 2109, Australia Tel: +61 2 9428 6555 Fax: +61 2 9428 6352
Cochlear NZ Limited Level 4, Takapuna Towers, 19-21 Como St, Takapuna, Auckland 0622, New Zealand Tel: + 64 9 914 1983 Fax: +61 2 8002 2800
Cochlear Ltd (ABN 96 002 618 073) 14 Mars Road, Lane Cove, NSW 2066, Australia Tel: +61 2 9428 6555 Fax: +61 2 9428 6352
Cochlear Americas 13059 E Peakview Avenue, Centennial, CO 80111, USA Tel: +1 303 790 9010 Fax: +1 303 792 9025
Cochlear Canada Inc 2500-120 Adelaide Street West, Toronto, ON M5H 1T1, Canada Tel: +1 416 972 5082 Fax: +1 416 972 5083
www.cochlear.com
Cochlear AG EMEA Headquarters, Peter Merian-Weg 4, 4052 Basel, Switzerland Tel: +41 61 205 0404 Fax: +41 61 205 0405
Cochlear Deutschland GmbH & Co. KG Karl-Wiechert-Allee 76A, 30625 Hannover, Germany Tel: +49 511 542 770 Fax: +49 511 542 7770
Cochlear Europe Ltd 6 Dashwood Lang Road, Bourne Business Park, Addlestone, Surrey KT15 2HJ, United Kingdom Tel: +44 1932 26 3400 Fax: +44 1932 26 3426
Cochlear Benelux NV Schaliënhoevedreef 20 i, B-2800 Mechelen, Belgium Tel: +32 15 79 55 11 Fax: +32 15 79 55 70
Disclaimer
Cochlear France S.A.S. 135 Route de Saint-Simon, 31100 Toulouse, France Tel: +33 5 34 63 85 85 (International) or 0805 200 016 (National) Fax: +33 5 34 63 85 80
Please
seek
advice
your
practitioner
health
professional
for hearing
Cochlear
Italia
S.r.l. from
Via Larga
33,medical
40138 Bologna,
Italy Tel:or
+39
051 601
53 11 Fax: +39about
051 39treatments
20 62
loss.
TheyNordic
will be
to advise on a14,suitable
solution Sweden
for theTel
hearing
condition.
products
Cochlear
ABable
Konstruktionsvägen
435 33 Mölnlycke,
+46 31 loss
335 14
61 Fax +46All
31 335
14 60
CochlearbeTıbbi
Cihazlar
Sağlık Hizmetleri
Ltd. Şti. Çubuklu
Mah. Boğaziçi
Cad.,professional.
Boğaziçi Plaza No: 6/1, Kavacık, TR-34805 Beykoz-Istanbul, Turkey Tel: +90 216 538 5900 Fax: +90 216 538 5919
should
used
only asvedirected
by your medical
practitioner
or health
Cochlear (HK) Limited Room 1204, 12/F, CRE Building, No 303 Hennessy Road, Wanchai, Hong Kong SAR Tel: +852 2530 5773 Fax: +852 2530 5183
Cochlear Korea Ltd 1st floor, Cheongwon building, 828-5, Yuksam dong, Kangnam gu, Seoul, Korea Tel: +82 2 533 4663 Fax: +82 2 533 8408
Not
all products
are available
in all6countries.
Please
contact
your
representative.
Cochlear
Limited (Singapore
Branch)
Sin Ming Road,
#01-16
Sin Ming
Plazalocal
TowerCochlear
2, Singapore
575585 Tel: +65 6553 3814 Fax: +65 6451 4105
Cochlear Medical Device (Beijing) Co., Ltd Unit 2208 Gemdale Tower B, 91 Jianguo Road, Chaoyang District, Beijing 100022, P.R. China Tel: +86 10 5909 7800 Fax: +86 10 5909 7900
Cochlear Medical Device Company India Pvt. Ltd. Ground Floor, Platina Building, Plot No C-59, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India Tel: +91 22 6112 1111 Fax: +91 22 6112 1100
ACE,
Advance Off-Stylet,
AutoNRT,
Autosensitivity,
Beam, Button, Carina,Cochlear,
株式会社日本コクレア
（NihonAOS,
Cochlear
Co Ltd）
〒113-0033 東京都文京区本郷2-3-7
お茶の水元町ビル Tel: +81 ,3Codacs,
3817 0241Contour,
Fax: +81 3Contour
3817 0245
Cochlear
East
FZ-LLCESPrit,
Dubai Healthcare
Al Razi
Building
64, BlockHugfit,
A, Ground
Floor, Offices
IR1 and
IR2, Dubai,
UnitedMET,
Arab Emirates
Tel: +971 4 818 4400 Fax: +971 4 361 8925
Advance,Middle
Custom
Sound,
Freedom,City,
Hear
now.
And always,
Hybrid,
inHear,
Invisible
Hearing,
MP3000,
Cochlear Latinoamérica S.A. International Business Park, Building 3835, Office 103, Panama Pacifico, Panama Tel: +507 830 6220 Fax: +507 830 6218
myCochlear, NRT, Nucleus,
, Off-Stylet, SmartSound, Softip, SPrint, True Wireless, the elliptical logo and Whisper are
Cochlear NZ Limited Level 4, Takapuna Towers, 19-21 Como St, Takapuna, Auckland 0622, New Zealand Tel: + 64 9 914 1983 Fax: +61 2 8002 2800
That’s why more people choose Cochlear than any other hearing implant company.
either trademarks or registered trademarks of Cochlear Limited. Ardium, Baha, Baha SoftWear, BCDrive, DermaLock, EveryWear,
Vistafix and WindShield are either trademarks or registered trademarks of Cochlear Bone Anchored Solutions AB.
www.cochlear.com
© Cochlear Limited 2016
D828700 ISS2 APR16